Literature DB >> 28681340

FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation.

Darshan C Patel1, Senthil S Gunasekaran1, Christopher Goettl1, Nadera J Sweiss2, Yang Lu3,4.   

Abstract

PURPOSE: This retrospective study investigates the relationship between cardiac and extra-thoracic sarcoid findings on FDG PET-CT using a 72-hour pretest high-fat, high-protein, and very low-carbohydrate (HFHPVLC) diet. PATIENTS AND METHODS: A total of 196 consecutive FDG PET-CT scans with 72-hour HFHPVLC diet preparation were performed between December 2014 and December 2015 in known sarcoid patients. Of these scans, 5 were excluded for non-adherence to diet preparation or underlying cancer. Cardiac and extra-thoracic sarcoid lesions were categorized and measured for radiotracer uptake.
RESULTS: A total of 188 patients had 191 eligible FDG PET/CT scans (3 follow-up scans), of which there were 20 (10%) positive, 6 indeterminate (3%), and 165 (86%) negative for CS. Among the 20 scans positive for CS, 8 (40%) had findings of both cardiac and extra-thoracic sarcoid.
CONCLUSION: Our study shows that 40% of CS patients also have FDG PET-CT findings of extra-thoracic sarcoid. This makes an intriguing case for FDG PET-CT use with pretest diet prep over cardiac MRI (CMR) for cardiac sarcoid evaluation, given that CMR is likely to overlook these extra-thoracic sites of disease.

Entities:  

Keywords:  Cardiac; Extra-thoracic; FDG PET-CT; Sarcoid; Sarcoidosis

Year:  2017        PMID: 28681340     DOI: 10.1007/s12350-017-0962-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  35 in total

1.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2007-11-06       Impact factor: 24.094

2.  Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Yoshio Ishida; Keiichiro Yoshinaga; Masao Miyagawa; Masao Moroi; Chisato Kondoh; Keisuke Kiso; Shinichiro Kumita
Journal:  Ann Nucl Med       Date:  2014-01-25       Impact factor: 2.668

Review 3.  Myocardial sarcoidosis.

Authors:  O P Sharma; A Maheshwari; K Thaker
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

4.  Early detection of cardiac sarcoid lesions with (18)F-fluoro-2-deoxyglucose positron emission tomography.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Takahiro Sato; Keiichiro Yoshinaga; Osamu Manabe; Noriko Oyama; Masaharu Nishimura
Journal:  Intern Med       Date:  2011-06-01       Impact factor: 1.271

Review 5.  Extrapulmonary sarcoidosis.

Authors:  Marc A Judson
Journal:  Semin Respir Crit Care Med       Date:  2007-02       Impact factor: 3.119

Review 6.  Chronic cutaneous lesions of sarcoidosis.

Authors:  Richard M Marchell; Marc A Judson
Journal:  Clin Dermatol       Date:  2007 May-Jun       Impact factor: 3.541

Review 7.  Cardiac sarcoidosis-state of the art review.

Authors:  Edward Hulten; Saira Aslam; Michael Osborne; Siddique Abbasi; Marcio Sommer Bittencourt; Ron Blankstein
Journal:  Cardiovasc Diagn Ther       Date:  2016-02

8.  Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis.

Authors:  Rumman Langah; Kenneth Spicer; Mulugeta Gebregziabher; Leonie Gordon
Journal:  J Nucl Cardiol       Date:  2009-06-23       Impact factor: 5.952

9.  Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis.

Authors:  Michael Soussan; Pierre-Yves Brillet; Hilario Nunes; Gabriel Pop; Matthieu-John Ouvrier; Nicolas Naggara; Dominique Valeyre; Pierre Weinmann
Journal:  J Nucl Cardiol       Date:  2012-11-28       Impact factor: 5.952

10.  Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Shinji Ishimaru; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Masatake Miura; Shinji Sakaue; Nagara Tamaki; Masaharu Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-15       Impact factor: 9.236

View more
  3 in total

1.  The logic and challenges of imaging sarcoidosis with whole body FDG PET.

Authors:  Roberto C Valentin; Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2017-08-17       Impact factor: 5.952

2.  18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis: Right ventricular uptake is associated with pathological uptake in mediastinal lymph nodes.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2018-05-02       Impact factor: 5.952

Review 3.  The role of PET in the management of sarcoidosis.

Authors:  Robert J Vender; Hamad Aldahham; Rohit Gupta
Journal:  Curr Opin Pulm Med       Date:  2022-07-16       Impact factor: 2.868

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.